. 2020 Sep 11;10(9):629. doi: 10.3390/brainsci10090629

Table 4.

Children with FXS in placebo-treated failed clinical trials: outcome measures improved.

Endpoint	Correlation	of Studies	Heterogeneity (I²)	Heterogeneity p-Value	Meta-Analysis Type	Mean Score Change	95% C		Change p-Value	% Improvement
Endpoint	Correlation	of Studies	Heterogeneity (I²)	Heterogeneity p-Value	Meta-Analysis Type	Mean Score Change	Lower	Upper	Change p-Value	% Improvement
Caregiver Rated
Vineland-II Comp	0.7	2	0.00	0.47	Fixed	1.71	0.38	3.05	0.012	2.51
Vineland-II Comp *	0.5	2	0.00	0.47	Fixed	1.71	0.38	3.05	0.012	2.51
VAS Comp	0.7	2	0.00	0.42	Fixed	1.56	0.94	2.18	<0.001	56.85
VAS Comp *	0.5	2	0.00	0.42	Fixed	1.54	0.90	2.17	<0.001	56.12

Abbreviations: FXS, fragile X syndrome; Vineland-II Comp, Vineland Adaptive Behavior Scale-2nd edition, Composite; VAS Comp, Visual Analog Scale, Composite. * Meta-analysis conducted using a pre-post correlation of 0.0 has almost identical values.